retatrutide type 2 diabetes ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Overall impressive retatrutide TRANSCEND-T2D-1 studied

2018;378(25):e34

Understanding the options helps patients make informed decisions aligned with their expectations and recovery capabilities

This broader mechanism may result in stronger appetite suppression and potentially greater overall weight loss

Indicators used to determine the signalling profile of peptides include cAMP and intracellular Ca 2+ mobilisation, which are involved in promotion of insulin release, and pERK1/2 that is part of the mitogenic signalling pathways activated via the GLP-1R 12

However, the cross-sectional design and the limited effect sizes call for cautious interpretation

For many researchers, revisiting dietary and exercise factors is more productive than adjusting peptide dose